News

October 16, 2020October 16, 2020

FDA Approves Keytruda for Adults as Second-Line Therapy for Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has expanded the use of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL) for whom initial therapies ... Read more

October 14, 2020October 14, 2020

Enrollment Underway in Melanoma Trial Testing Leukine Triple Combo

News

A Phase 2/3 clinical trial is again recruiting participants to continue investigating the immunomodulator Leukine (sargramostim) in combination with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) as an initial treatment ... Read more

October 12, 2020October 12, 2020

Agenus Begins Rolling Submission of Balstilimab to FDA for Advanced Cervical Cancer

News

Agenus is seeking U.S. approval of balstilimab, its investigational immunotherapy for the treatment of recurrent or metastatic cervical cancer, which has limited effective treatment options and disproportionately affects younger people. ... Read more

October 9, 2020October 9, 2020

FDA Approves Opdivo-Yervoy Combo as First-Line Therapy for Inoperable Mesothelioma

News

The U.S. Food and Drug Administration (FDA) has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line therapy for adults with inoperable malignant pleural mesothelioma (MPM), a rare but aggressive cancer ... Read more

October 7, 2020October 7, 2020

Phase 1 Trial of ET140203 T-cell Therapy Starts Enrolling Adults With Advanced Liver Cancer

News

Eureka Therapeutics has started enrolling adults with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, in a Phase 1/2 trial of its investigational ET140203 T-cell therapy. The ... Read more

October 2, 2020October 2, 2020

Libtayo First-line Treatment Prolongs Survival in Advanced NSCLC, Early Trial Data Show

News

When given as a first-line therapy, Libtayo (cemiplimab) prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC), compared with platinum-based chemotherapy, according to early data from a ... Read more

September 30, 2020September 30, 2020

Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancers

News

Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk ... Read more

September 28, 2020September 28, 2020

First-line Keytruda Doubles 5-Year Survival in Certain Lung Cancer Patients, Data Show

News

First-line treatment with Keytruda (pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastatic non-small cell lung cancer (NSCLC) and high levels of PD-L1, compared with standard chemotherapy, ... Read more

September 25, 2020September 25, 2020

Tecentriq-Avastin Combo Recommended for EU Approval for Liver Cancer

News

Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), has been recommended for approval in the European Union as a first-line treatment for adults with advanced hepatocellular carcinoma (HCC), the most common ... Read more

September 23, 2020September 23, 2020

EU Approval Recommended for Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

News

A European Medicines Agency (EMA) committee has recommended that a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy be approved in the European Union (EU) as first-line treatment for advanced non-small ... Read more